ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death-Executive Summary.

Journal of the American College of Cardiology

Volumn 48, Issue 5, 2006, Pages 1064-1108

  Zipes, Douglas P ^a   Camm, A John ^a   Borggrefe, Martin ^a   Buxton, Alfred E ^a   Chaitman, Bernard ^a   Fromer, Martin ^a   Gregoratos, Gabriel ^a   Klein, George ^a   Moss, Arthur J ^a   Myerburg, Robert J ^a   Priori, Silvia G ^a   Quinones, Miguel A ^a   Roden, Dan M ^a   Silka, Michael J ^a   Tracy, Cynthia ^a   Smith Jr , Sidney C ^a   Jacobs, Alice K ^a   Adams, Cynthia D ^a   Antman, Elliott M ^a   Anderson, Jeffrey L ^a   Hunt, Sharon A ^a   Halperin, Jonathan L ^a   Nishimura, Rick ^a   Ornato, Joseph P ^a   Page, Richard L ^a   Riegel, Barbara ^a   Blanc, Jean Jacques ^a   Budaj, Andrzej ^a   Dean, Veronica ^a   Deckers, Jaap W ^a   Despres, Catherine ^a   Dickstein, Kenneth ^a   Lekakis, John ^a   McGregor, Keith ^a   Metra, Marco ^a   Morais, Joao ^a   Osterspey, Ady ^a   Tamargo, Juan Luis ^a   Zamorano, José Luis ^a   more..

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; ASTEMIZOLE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CISAPRIDE; CLARITHROMYCIN; CYCLOSPORIN; DIGITALIS; DILTIAZEM; DOFETILIDE; ERYTHROMYCIN; FLECAINIDE; ISOPRENALINE; ITRACONAZOLE; KETOCONAZOLE; LIDOCAINE; MAGNESIUM SULFATE; MEXILETINE; PHENYTOIN; PROCAINAMIDE; PROPAFENONE; QUINIDINE; SILDENAFIL; SODIUM CHANNEL BLOCKING AGENT; SOTALOL; TERFENADINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VERAPAMIL;

ANGIOCARDIOGRAPHY; CARDIOTOXICITY; CLINICAL TRIAL; DEFIBRILLATOR; ECHOCARDIOGRAPHY; EXERCISE TEST; GLYCOGEN STORAGE DISEASE TYPE 4; HEART DEATH; HEART ELECTROPHYSIOLOGY; HEART FAILURE; HEART VENTRICLE ARRHYTHMIA; HUMAN; ISCHEMIC HEART DISEASE; META ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRACTICE GUIDELINE; PRIORITY JOURNAL; QT PROLONGATION; REVASCULARIZATION; REVIEW; SCINTIANGIOGRAPHY; SMOKING; SUDDEN DEATH; SYSTEMATIC REVIEW; TACHYCARDIA;

EID: 33748609679     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2006.07.008     Document Type: Review

References (314)

1. Gregoratos G., Abrams J., Epstein A.E., et al. ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines). Circulation 106 (2002) 2145-2161
2. Antman E.M., Anbe D.T., Armstrong P.W., et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction. a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction). J Am Coll Cardiol 44 (2004) E1-E211
3. Priori S.G., Aliot E., Blomstrom-Lundqvist C., et al. Task Force on Sudden Cardiac Death of the European Society of Cardiology. Eur Heart J 22 (2001) 1374-1450
4. Priori S.G., Aliot E., Blomstrom-Lundqvist C., et al. Update of the guidelines on sudden cardiac death of the European Society of Cardiology. Eur Heart J 24 (2003) 13-15
5. Swedberg K., Cleland J., Dargie H., et al. Executive summary of the guidelines for the diagnosis and treatment of chronic heart failure. the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 26 (2005) 1115-1140
6. Hunt S.A. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult. a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 46 (2005) e1-e82
7. Buxton AE. A report of the American College of Cardiology Task Force on Clinical Data Standards (Electrophysiolology Writing Committee). Manuscript in preparation.
8. Poole J.E., and Bardy G.H. Sudden Cardiac Death. In: Zipes D.P., and Jalife J. (Eds). Cardiac Electrophysiology. From Cell to Bedside. 3rd edition (2000), W.B. Saunders Company, Philadelphia, PA 615-640
9. Bardy G.H., Lee K.L., Mark D.B., et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352 (2005) 225-237
10. Gillum R.F. Sudden coronary death in the United States. 1980-1985. Circulation 79 (1989) 756-765
11. Escobedo L.G., and Zack M.M. Comparison of sudden and nonsudden coronary deaths in the United States. Circulation 93 (1996) 2033-2036
12. Zheng Z.J., Croft J.B., Giles W.H., et al. Sudden cardiac death in the United States, 1989 to 1998. Circulation 104 (2001) 2158-2163
13. Cobb L.A., Fahrenbruch C.E., Olsufka M., and Copass M.K. Changing incidence of out-of-hospital ventricular fibrillation, 1980-2000. JAMA 288 (2002) 3008-3013
14. American Heart Association. Heart Disease and Stroke Statistics-2005 Update (2004), American Heart Association, Dallas, TX
15. Myerburg R.J., Kessler K.M., and Castellanos A. Sudden cardiac death. epidemiology, transient risk, and intervention assessment. Ann Intern Med 119 (1993) 1187-1197
16. Kuller L., Lilienfeld A., and Fisher R. An epidemiological study of sudden and unexpected deaths in adults. Medicine (Baltimore) 46 (1967) 341-361
17. de Vreede-Swagemakers J.J., Gorgels A.P., Dubois-Arbouw W.I., et al. Out-of-hospital cardiac arrest in the 1990's. a population-based study in the Maastricht area on incidence, characteristics and survival. J Am Coll Cardiol 30 (1997) 1500-1505
18. Gillum R.F. Geographic variation in sudden coronary death. Am Heart J 119 (1990) 380-389
19. Myerburg R.J. Sudden cardiac death. exploring the limits of our knowledge. J Cardiovasc Electrophysiol 12 (2001) 369-381
20. Huikuri H.V., Castellanos A., and Myerburg R.J. Sudden death due to cardiac arrhythmias. N Engl J Med 345 (2001) 1473-1482
21. Braunwald E. Shattuck lecture-cardiovascular medicine at the turn of the millennium. triumphs, concerns, and opportunities. N Engl J Med 337 (1997) 1360-1369
22. Myerburg R.J., Mitrani R., Interian Jr. A., and Castellanos A. Interpretation of outcomes of antiarrhythmic clinical trials. design features and population impact. Circulation 97 (1998) 1514-1521
23. Gibbons R.J., Balady G.J., Bricker J.T., et al. ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). J Am Coll Cardiol 40 (2002) 1531-1540
24. Jouven X., Zureik M., Desnos M., et al. Long-term outcome in asymptomatic men with exercise-induced premature ventricular depolarizations. N Engl J Med 343 (2000) 826-833
25. Frolkis J.P., Pothier C.E., Blackstone E.H., et al. Frequent ventricular ectopy after exercise as a predictor of death. N Engl J Med 348 (2003) 781-790
26. Huikuri H.V., Makikallio T.H., Raatikainen M.J., et al. Prediction of sudden cardiac death. appraisal of the studies and methods assessing the risk of sudden arrhythmic death. Circulation 108 (2003) 110-115
27. Cheitlin M.D., Alpert J.S., Armstrong W.F., et al. ACC/AHA guidelines for the Clinical Application of Echocardiography: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Clinical Application of Echocardiography). Developed in collaboration with the American Society of Echocardiography. Circulation 95 (1997) 1686-1744
28. Cheitlin M.D., Armstrong W.F., Aurigemma G.P., et al. ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography-summary article. a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). J Am Coll Cardiol 42 (2003) 954-970
29. Schiller N.B., Shah P.M., Crawford M., et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 2 (1989) 358-367
30. Ross D.L., Farre J., Bar F.W., et al. Comprehensive clinical electrophysiologic studies in the investigation of documented or suspected tachycardias. Time, staff, problems and costs. Circulation 61 (1980) 1010-1016
31. Freedman R.A., Swerdlow C.D., Soderholm-Difatte V., et al. Prognostic significance of arrhythmia inducibility or noninducibility at initial electrophysiologic study in survivors of cardiac arrest. Am J Cardiol 61 (1988) 578-582
32. Wilber D.J., Garan H., Finkelstein D., et al. Out-of-hospital cardiac arrest. Use of electrophysiologic testing in the prediction of long-term outcome. N Engl J Med 318 (1988) 19-24
33. Mittal S., Iwai S., Stein K.M., et al. Long-term outcome of patients with unexplained syncope treated with an electrophysiologic-guided approach in the implantable cardioverter-defibrillator era. J Am Coll Cardiol 34 (1999) 1082-1089
34. Gurevitz O., Viskin S., Glikson M., et al. Long-term prognosis of inducible ventricular flutter. not an innocent finding. Am Heart J 147 (2004) 649-654
35. Viskin S., Justo D., Halkin A., et al. Long QT syndrome caused by noncardiac drugs. Prog Cardiovasc Dis 45 (2003) 415-427
36. Vaughan Williams E.M. A classification of antiarrhythmic actions reassessed after a decade of new drugs. J Clin Pharmacol 24 (1984) 129-147
37. The Sicilian Gambit, and Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Circulation 84 (1991) 1831-1851
38. Reiter M.J., and Reiffel J.A. Importance of beta blockade in the therapy of serious ventricular arrhythmias. Am J Cardiol 82 (1998) 9I-19I
39. Ellison K.E., Hafley G.E., Hickey K., et al. Effect of beta-blocking therapy on outcome in the Multicenter UnSustained Tachycardia Trial (MUSTT). Circulation 106 (2002) 2694-2699
40. Connolly S.J. Meta-analysis of antiarrhythmic drug trials. Am J Cardiol 84 (1999) 90R-93R
41. Steinberg J.S., Martins J., Sadanandan S., et al. Antiarrhythmic drug use in the implantable defibrillator arm of the Antiarrhythmics Versus Implantable Defibrillators (AVID) Study. Am Heart J 142 (2001) 520-529
42. Farre J., Romero J., Rubio J.M., et al. Amiodarone and "primary" prevention of sudden death. critical review of a decade of clinical trials. Am J Cardiol 83 (1999) 55D-63D
43. Cleland J.G., Ghosh J., Freemantle N., et al. Clinical trials update and cumulative meta-analyses from the American College of Cardiology. WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure. Eur J Heart Fail 6 (2004) 501-508
44. Amiodarone Trials Meta-Analysis Investigators. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure. meta-analysis of individual data from 6500 patients in randomised trials. Lancet 350 (1997) 1417-1424
45. Janse M.J., Malik M., Camm A.J., et al. Identification of post acute myocardial infarction patients with potential benefit from prophylactic treatment with amiodarone. A substudy of EMIAT (the European Myocardial Infarct Amiodarone Trial). Eur Heart J 19 (1998) 85-95
46. Boutitie F., Boissel J.P., Connolly S.J., et al., The EMIAT and CAMIAT Investigators. Amiodarone interaction with beta-blockers. analysis of the merged EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) databases. Circulation 99 (1999) 2268-2275
47. Pacifico A., Hohnloser S.H., Williams J.H., et al. Prevention of implantable-defibrillator shocks by treatment with sotalol. d,l-Sotalol Implantable Cardioverter-Defibrillator Study Group. N Engl J Med 340 (1999) 1855-1862
48. Moss A.J., Hall W.J., Cannom D.S., et al., Multicenter Automatic Defibrillator Implantation Trial Investigators. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 335 (1996) 1933-1940
49. Bigger Jr. J.T., and Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. N Engl J Med 337 (1997) 1569-1575
50. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 337 (1997) 1576-1583
51. Buxton A.E., Lee K.L., Fisher J.D., et al., Multicenter Unsustained Tachycardia Trial Investigators. A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med 341 (1999) 1882-1890
52. Moss A.J., Zareba W., Hall W.J., et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346 (2002) 877-883
53. Lee D.S., Green L.D., Liu P.P., et al. Effectiveness of implantable defibrillators for preventing arrhythmic events and death. a meta-analysis. J Am Coll Cardiol 41 (2003) 1573-1582
54. Ezekowitz J.A., Armstrong P.W., and McAlister F.A. Implantable cardioverter defibrillators in primary and secondary prevention. a systematic review of randomized, controlled trials. Ann Intern Med 138 (2003) 445-452
55. Marenco J.P., Wang P.J., Link M.S., et al. Improving survival from sudden cardiac arrest. the role of the automated external defibrillator. JAMA 285 (2001) 1193-1200
56. Priori S.G., Bossaert L.L., Chamberlain D.A., et al. ESC-ERC recommendations for the use of automated external defibrillators (AEDs) in Europe. Eur Heart J 25 (2004) 437-445
57. Koster R.W. Automatic external defibrillator. key link in the chain of survival. J Cardiovasc Electrophysiol 13 (2002) S92-S95
58. Valenzuela T.D., Roe D.J., Nichol G., et al. Outcomes of rapid defibrillation by security officers after cardiac arrest in casinos. N Engl J Med 343 (2000) 1206-1209
59. Caffrey S.L., Willoughby P.J., Pepe P.E., et al. Public use of automated external defibrillators. N Engl J Med 347 (2002) 1242-1247
60. Silva R.M., Mont L., Nava S., et al. Radiofrequency catheter ablation for arrhythmic storm in patients with an implantable cardioverter defibrillator. Pacing Clin Electrophysiol 27 (2004) 971-975
61. Brugada J., Brugada R., and Brugada P. Determinants of sudden cardiac death in individuals with the electrocardiographic pattern of Brugada syndrome and no previous cardiac arrest. Circulation 108 (2003) 3092-3096
62. Pappone C., Santinelli V., Manguso F., et al. A randomized study of prophylactic catheter ablation in asymptomatic patients with the Wolff-Parkinson-White syndrome. N Engl J Med 349 (2003) 1803-1811
63. Haissaguerre M., Shoda M., Jais P., et al. Mapping and ablation of idiopathic ventricular fibrillation. Circulation 106 (2002) 962-967
64. Takemoto M., Yoshimura H., Ohba Y., et al. Radiofrequency catheter ablation of premature ventricular complexes from right ventricular outflow tract improves left ventricular dilation and clinical status in patients without structural heart disease. J Am Coll Cardiol 45 (2005) 1259-1265
65. Scheinman M.M. NASPE survey on catheter ablation. Pacing Clin Electrophysiol 18 (1995) 1474-1478
66. Twidale N., Hazlitt H.A., Berbari E.J., et al. Late potentials are unaffected by radiofrequency catheter ablation in patients with ventricular tachycardia. Pacing Clin Electrophysiol 17 (1994) 157-165
67. SippensGroenewegen A., Spekhorst H., van Hemel N.M., et al. Localization of the site of origin of postinfarction ventricular tachycardia by endocardial pace mapping. Body surface mapping compared with the 12-lead electrocardiogram. Circulation 88 (1993) 2290-2306
68. Morady F., Harvey M., Kalbfleisch S.J., et al. Radiofrequency catheter ablation of ventricular tachycardia in patients with coronary artery disease. Circulation 87 (1993) 363-372
69. Stevenson W.G., Khan H., Sager P., et al. Identification of reentry circuit sites during catheter mapping and radiofrequency ablation of ventricular tachycardia late after myocardial infarction. Circulation 88 (1993) 1647-1670
70. Cohen T.J., Chien W.W., Lurie K.G., et al. Radiofrequency catheter ablation for treatment of bundle branch reentrant ventricular tachycardia. results and long-term follow-up. J Am Coll Cardiol 18 (1991) 1767-1773
71. Tchou P., Jazayeri M., Denker S., et al. Transcatheter electrical ablation of right bundle branch. A method of treating macroreentrant ventricular tachycardia attributed to bundle branch reentry. Circulation 78 (1988) 246-257
72. Nakagawa H., Beckman K.J., McClelland J.H., et al. Radiofrequency catheter ablation of idiopathic left ventricular tachycardia guided by a Purkinje potential. Circulation 88 (1993) 2607-2617
73. Page R.L., Shenasa H., Evans J.J., et al. Radiofrequency catheter ablation of idiopathic recurrent ventricular tachycardia with right bundle branch block, left axis morphology. Pacing Clin Electrophysiol 16 (1993) 327-336
74. Klein L.S., Shih H.T., Hackett F.K., et al. Radiofrequency catheter ablation of ventricular tachycardia in patients without structural heart disease. Circulation 85 (1992) 1666-1674
75. Calkins H., Kalbfleisch S.J., el-Atassi R., et al. Relation between efficacy of radiofrequency catheter ablation and site of origin of idiopathic ventricular tachycardia. Am J Cardiol 71 (1993) 827-833
76. Kim Y.H., Sosa-Suarez G., Trouton T.G., et al. Treatment of ventricular tachycardia by transcatheter radiofrequency ablation in patients with ischemic heart disease. Circulation 89 (1994) 1094-1102
77. Coggins D.L., Lee R.J., Sweeney J., et al. Radiofrequency catheter ablation as a cure for idiopathic tachycardia of both left and right ventricular origin. J Am Coll Cardiol 23 (1994) 1333-1341
78. Schwartz P.J., Priori S.G., Cerrone M., et al. Left cardiac sympathetic denervation in the management of high-risk patients affected by the long-QT syndrome. Circulation 109 (2004) 1826-1833
79. Carnendran L., and Steinberg J.S. Does an open infarct-related artery after myocardial infarction improve electrical stability?. Prog Cardiovasc Dis 42 (2000) 439-454
80. Hillis L.D., Cigarroa J.E., and Lange R.A. Late revascularization reduces mortality in survivors of myocardial infarction. Cardiol Rev 7 (1999) 144-148
81. 2005 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation 112 (2005) IV1-IV203
82. Nolan J.P., Deakin C.D., Soar J., et al. European Resuscitation Council Guidelines for Resuscitation 2005 Section 4. Adult advanced life support. Resuscitation 67 Suppl 1 (2005) S39-S86
83. Antman E.M., and Berlin J.A. Declining incidence of ventricular fibrillation in myocardial infarction. Implications for the prophylactic use of lidocaine. Circulation 86 (1992) 764-773
84. Behar S., Goldbourt U., Reicher-Reiss H., et al., Principal Investigators of the SPRINT Study. Prognosis of acute myocardial infarction complicated by primary ventricular fibrillation. Am J Cardiol 66 (1990) 1208-1211
85. MacMahon S., Collins R., Peto R., et al. Effects of prophylactic lidocaine in suspected acute myocardial infarction. An overview of results from the randomized, controlled trials. JAMA 260 (1988) 1910-1916
86. Higham P.D., Adams P.C., Murray A., et al. Plasma potassium, serum magnesium and ventricular fibrillation. a prospective study. Q J Med 86 (1993) 609-617
87. Gorgels A.P., van den Dool A., Hofs A., et al. Comparison of procainamide and lidocaine in terminating sustained monomorphic ventricular tachycardia. Am J Cardiol 78 (1996) 43-46
88. Callans D.J., and Marchlinski F.E. Dissociation of termination and prevention of inducibility of sustained ventricular tachycardia with infusion of procainamide. evidence for distinct mechanisms. J Am Coll Cardiol 19 (1992) 111-117
89. Sharma A.D., Purves P., Yee R., et al. Hemodynamic effects of intravenous procainamide during ventricular tachycardia. Am Heart J 119 (1990) 1034-1041
90. Nasir Jr. N., Taylor A., Doyle T.K., et al. Evaluation of intravenous lidocaine for the termination of sustained monomorphic ventricular tachycardia in patients with coronary artery disease with or without healed myocardial infarction. Am J Cardiol 74 (1994) 1183-1186
91. Lie K.I., Wellens H.J., van Capelle F.J., et al. Lidocaine in the prevention of primary ventricular fibrillation. A double-blind, randomized study of 212 consecutive patients. N Engl J Med 291 (1974) 1324-1326
92. Buxton A.E., Marchlinski F.E., Doherty J.U., et al. Repetitive, monomorphic ventricular tachycardia. clinical and electrophysiologic characteristics in patients with and patients without organic heart disease. Am J Cardiol 54 (1984) 997-1002
93. Rahilly G.T., Prystowsky E.N., Zipes D.P., et al. Clinical and electrophysiologic findings in patients with repetitive monomorphic ventricular tachycardia and otherwise normal electrocardiogram. Am J Cardiol 50 (1982) 459-468
94. Lerman B.B., Stein K., Engelstein E.D., et al. Mechanism of repetitive monomorphic ventricular tachycardia. Circulation 92 (1995) 421-429
95. Ouyang F., Fotuhi P., Ho S.Y., et al. Repetitive monomorphic ventricular tachycardia originating from the aortic sinus cusp. electrocardiographic characterization for guiding catheter ablation. J Am Coll Cardiol 39 (2002) 500-508
96. Sadanaga T., Saeki K., Yoshimoto T., et al. Repetitive monomorphic ventricular tachycardia of left coronary cusp origin. Pacing Clin Electrophysiol 22 (1999) 1553-1556
97. Grimm W., Menz V., Hoffmann J., et al. Reversal of tachycardia induced cardiomyopathy following ablation of repetitive monomorphic right ventricular outflow tract tachycardia. Pacing Clin Electrophysiol 24 (2001) 166-171
98. Buxton A.E., Waxman H.L., Marchlinski F.E., et al. Right ventricular tachycardia. clinical and electrophysiologic characteristics. Circulation 68 (1983) 917-927
99. Fung J.W., Chan H.C., Chan J.Y., et al. Ablation of nonsustained or hemodynamically unstable ventricular arrhythmia originating from the right ventricular outflow tract guided by noncontact mapping. Pacing Clin Electrophysiol 26 (2003) 1699-1705
100. Nademanee K., Taylor R., Bailey W.E., et al. Treating electrical storm. sympathetic blockade versus advanced cardiac life support-guided therapy. Circulation 102 (2000) 742-747
101. Kowey P.R., Marinchak R.A., Rials S.J., et al. Intravenous antiarrhythmic therapy in the acute control of in-hospital destabilizing ventricular tachycardia and fibrillation. Am J Cardiol 84 (1999) 46R-51R
102. The American Heart Association in collaboration with the International Liaison Committee on Resuscitation. Guidelines 2000 for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Part 6: advanced cardiovascular life support: section 5: pharmacology I: agents for arrhythmias. Circulation 102 (2000) I112-I118
103. The American Heart Association in collaboration with the International Liaison Committee on Resuscitation. Guidelines 2000 for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Part 6: advanced cardiovascular life support: section 7: algorithm approach to ACLS emergencies: section 7A: principles and practice of ACLS. Circulation 102 (2000) I136-I139
104. Dorian P., and Cass D. An overview of the management of electrical storm. Can J Cardiol 13 Suppl A (1997) 13A-17A
105. Bonow R.O., Carabello B., Chatterjee K., et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients with Valvular Heart Disease). J Am Coll Cardiol 48 (2006) e1-e148
106. State-specific mortality from sudden cardiac death-United States, 1999. MMWR Morb Mortal Wkly Rep 51 (2002) 123-126
107. Silka M.J., Hardy B.G., Menashe V.D., et al. A population-based prospective evaluation of risk of sudden cardiac death after operation for common congenital heart defects. J Am Coll Cardiol 32 (1998) 245-251
108. Oechslin E.N., Harrison D.A., Connelly M.S., et al. Mode of death in adults with congenital heart disease. Am J Cardiol 86 (2000) 1111-1116
109. Graham Jr. T.P., Bernard Y.D., Mellen B.G., et al. Long-term outcome in congenitally corrected transposition of the great arteries. a multi-institutional study. J Am Coll Cardiol 36 (2000) 255-261
110. Alexander M.E., Walsh E.P., Saul J.P., et al. Value of programmed ventricular stimulation in patients with congenital heart disease. J Cardiovasc Electrophysiol 10 (1999) 1033-1044
111. Fish F.A., Gillette P.C., Benson Jr. D.W., and The Pediatric Electrophysiology Group. Proarrhythmia, cardiac arrest and death in young patients receiving encainide and flecainide. J Am Coll Cardiol 18 (1991) 356-365
112. Jonas M., and Hod H. Is immunosuppressive treatment an option for myocarditis?. Isr J Med Sci 33 (1997) 762-766
113. Tai Y.T., Lau C.P., Fong P.C., et al. Incessant automatic ventricular tachycardia complicating acute coxsackie B myocarditis. Cardiology 80 (1992) 339-344
114. Tubman T.R., Craig B., and Mulholland H.C. Ventricular tachycardia associated with Coxsackie B4 virus infection. Acta Paediatr Scand 79 (1990) 572-575
115. Gowrishankar K., and Rajajee S. Varied manifestations of viral myocarditis. Indian J Pediatr 61 (1994) 75-80
116. Mary A.S., and Hamilton M. Ventricular tachycardia in a patient with toxoplasmosis. Br Heart J 35 (1973) 349-352
117. Etherington J., Salmon J., and Ratcliffe G. Atrio-ventricular dissociation in meningococcal meningitis. J R Army Med Corps 141 (1995) 169-171
118. Dhar K.L., Adlakha A., and Phillip P.J. Recurrent seizures and syncope, ventricular arrhythmias with reversible prolonged Q-Tc interval in typhoid myocarditis. J Indian Med Assoc 85 (1987) 336-337
119. Kawai C. From myocarditis to cardiomyopathy: mechanisms of inflammation and cell death: learning from the past for the future. Circulation 99 (1999) 1091-1100
120. Winkel E., and Parrillo J. Myocarditis. Curr Treat Options Cardiovasc Med 4 (2002) 455-466
121. Mayer W., Kleber F.X., Wilske B., et al. Persistent atrioventricular block in Lyme borreliosis. Klin Wochenschr 68 (1990) 431-435
122. Nagi K.S., and Thakur R.K. Lyme carditis. indications for cardiac pacing. Can J Cardiol 11 (1995) 335-338
123. Rassi Jr. A., Rassi A., and Little W.C. Chagas' heart disease. Clin Cardiol 23 (2000) 883-889
124. Muratore C., Rabinovich R., Iglesias R., et al. Implantable cardioverter defibrillators in patients with Chagas' disease. are they different from patients with coronary disease?. Pacing Clin Electrophysiol 20 (1997) 194-197
125. Malik J.A., Hassan C., and Khan G.Q. Transient complete heart block complicating acute rheumatic fever. Indian Heart J 54 (2002) 91-92
126. Liberman L., Hordof A.J., Alfayyadh M., et al. Torsade de pointes in a child with acute rheumatic fever. J Pediatr 138 (2001) 280-282
127. Freed M.S., Sacks P., and Ellman M.H. Ventricular tachycardia in acute rheumatic fever. Arch Intern Med 145 (1985) 1904-1905
128. Wallace S.M., Walton B.I., Kharbanda R.K., et al. Mortality from infective endocarditis. clinical predictors of outcome. Heart 88 (2002) 53-60
129. Drenick E.J., and Fisler J.S. Sudden cardiac arrest in morbidly obese surgical patients unexplained after autopsy. Am J Surg 155 (1988) 720-726
130. Sjostrom L.V. Mortality of severely obese subjects. Am J Clin Nutr 55 (1992) 516S-523S
131. Lattimore J.D., Celermajer D.S., and Wilcox I. Obstructive sleep apnea and cardiovascular disease. J Am Coll Cardiol 41 (2003) 1429-1437
132. Neumarker K.J. Mortality and sudden death in anorexia nervosa. Int J Eat Disord 21 (1997) 205-212
133. Wyse D.G., Friedman P.L., Brodsky M.A., et al. Life-threatening ventricular arrhythmias due to transient or correctable causes. high risk for death in follow-up. J Am Coll Cardiol 38 (2001) 1718-1724
134. Kliegel A., Eisenburger P., Sterz F., et al. Survivors of ventricular tachyarrhythmias due to a transient or reversible disorder have a high recurrence rate of lethal cardiac events. Resuscitation 54 (2002) 237-243
135. Brugada J., Aguinaga L., Mont L., et al. Coronary artery revascularization in patients with sustained ventricular arrhythmias in the chronic phase of a myocardial infarction. effects on the electrophysiologic substrate and outcome. J Am Coll Cardiol 37 (2001) 529-533
136. Kelly P., Ruskin J.N., Vlahakes G.J., et al. Surgical coronary revascularization in survivors of prehospital cardiac arrest. its effect on inducible ventricular arrhythmias and long-term survival. J Am Coll Cardiol 15 (1990) 267-273
137. Dec G.W., and Fuster V. Idiopathic dilated cardiomyopathy. N Engl J Med 331 (1994) 1564-1575
138. Di L.A., Secoli G., Perkan A., et al., The Heart Muscle Disease Study Group. Changing mortality in dilated cardiomyopathy. Br Heart J 72 (1994) S46-S51
139. Sugrue D.D., Rodeheffer R.J., Codd M.B., et al. The clinical course of idiopathic dilated cardiomyopathy. A population-based study. Ann Intern Med 117 (1992) 117-123
140. Komajda M., Jais J.P., Reeves F., et al. Factors predicting mortality in idiopathic dilated cardiomyopathy. Eur Heart J 11 (1990) 824-831
141. Luu M., Stevenson W.G., Stevenson L.W., et al. Diverse mechanisms of unexpected cardiac arrest in advanced heart failure. Circulation 80 (1989) 1675-1680
142. Kelly P., and Coats A. Variation in mode of sudden cardiac death in patients with dilated cardiomyopathy. Eur Heart J 18 (1997) 879-880
143. Tamburro P., and Wilber D. Sudden death in idiopathic dilated cardiomyopathy. Am Heart J 124 (1992) 1035-1045
144. Doval H.C., Nul D.R., Grancelli H.O., et al., Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Randomised trial of low-dose amiodarone in severe congestive heart failure. Lancet 344 (1994) 493-498
145. Singh S.N., Fletcher R.D., Fisher S.G., et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med 333 (1995) 77-82
146. Connolly S.J., Gent M., Roberts R.S., et al. Canadian implantable defibrillator study (CIDS). a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 101 (2000) 1297-1302
147. Kuck K.H., Cappato R., Siebels J., et al. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest. the Cardiac Arrest Study Hamburg (CASH). Circulation 102 (2000) 748-754
148. Connolly S.J., Hallstrom A.P., Cappato R., et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J 21 (2000) 2071-2078
149. Kadish A., Quigg R., Schaechter A., et al. Defibrillators in nonischemic cardiomyopathy treatment evaluation. Pacing Clin Electrophysiol 23 (2000) 338-343
150. Grimm W., Alter P., and Maisch B. Arrhythmia risk stratification with regard to prophylactic implantable defibrillator therapy in patients with dilated cardiomyopathy. Results of MACAS, DEFINITE, and SCD-HeFT. Herz 29 (2004) 348-352
151. Kadish A., Dyer A., Daubert J.P., et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 350 (2004) 2151-2158
152. Hohnloser S.H., Kuck K.H., Dorian P., et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 351 (2004) 2481-2488
153. Spirito P., and Bellone P. Natural history of hypertrophic cardiomyopathy. Br Heart J 72 (1994) S10-S12
154. Louie E.K., and Edwards III L.C. Hypertrophic cardiomyopathy. Prog Cardiovasc Dis 36 (1994) 275-308
155. Wigle E.D., Rakowski H., Kimball B.P., et al. Hypertrophic cardiomyopathy. Clinical spectrum and treatment. Circulation 92 (1995) 1680-1692
156. DeRose Jr. J.J., Banas Jr. J.S., and Winters S.L. Current perspectives on sudden cardiac death in hypertrophic cardiomyopathy. Prog Cardiovasc Dis 36 (1994) 475-484
157. Maron B.J., Bonow R.O., Cannon III R.O., et al. Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy (2). N Engl J Med 316 (1987) 844-852
158. Maron B.J., Bonow R.O., Cannon III R.O., et al. Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy (1). N Engl J Med 316 (1987) 780-789
159. Maron B.J., Roberts W.C., and Epstein S.E. Sudden death in hypertrophic cardiomyopathy. a profile of 78 patients. Circulation 65 (1982) 1388-1394
160. Sadoul N., Prasad K., Elliott P.M., et al. Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. Circulation 96 (1997) 2987-2991
161. Mittal S.R. Sudden cardiac death in hypertrophic cardiomyopathy. risk evaluation. Int J Cardiol 52 (1995) 1-4
162. Spirito P., Bellone P., Harris K.M., et al. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 342 (2000) 1778-1785
163. Maron B.J., McKenna W.J., Danielson G.K., et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 42 (2003) 1687-1713
164. Spirito P., Seidman C.E., McKenna W.J., et al. The management of hypertrophic cardiomyopathy. N Engl J Med 336 (1997) 775-785
165. Robinson K., Frenneaux M.P., Stockins B., et al. Atrial fibrillation in hypertrophic cardiomyopathy. a longitudinal study. J Am Coll Cardiol 15 (1990) 1279-1285
166. McKenna W.J., Harris L., Rowland E., et al. Amiodarone for long-term management of patients with hypertrophic cardiomyopathy. Am J Cardiol 54 (1984) 802-810
167. Maron B.J., Shen W.K., Link M.S., et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med 342 (2000) 365-373
168. Maron B.J., Estes III N.A., Maron M.S., et al. Primary prevention of sudden death as a novel treatment strategy in hypertrophic cardiomyopathy. Circulation 107 (2003) 2872-2875
169. Corrado D., Basso C., Thiene G., et al. Spectrum of clinicopathologic manifestations of arrhythmogenic right ventricular cardiomyopathy/dysplasia. a multicenter study. J Am Coll Cardiol 30 (1997) 1512-1520
170. Schionning J.D., Frederiksen P., and Kristensen I.B. Arrhythmogenic right ventricular dysplasia as a cause of sudden death. Am J Forensic Med Pathol 18 (1997) 345-348
171. Munclinger M.J., Patel J.J., and Mitha A.S. Follow-up of patients with arrhythmogenic right ventricular cardiomyopathy dysplasia. S Afr Med J 90 (2000) 61-68
172. Link M.S., Wang P.J., Haugh C.J., et al. Arrhythmogenic right ventricular dysplasia. clinical results with implantable cardioverter defibrillators. J Interv Card Electrophysiol 1 (1997) 41-48
173. Hauer R.N., Aliot E., Block M., et al. Indications for implantable cardioverter defibrillator (ICD) therapy. Study Group on Guidelines on ICDs of the Working Group on Arrhythmias and the Working Group on Cardiac Pacing of the European Society of Cardiology. Eur Heart J 22 (2001) 1074-1081
174. Myerburg R.J., and Castellanos A. Clinical trials of implantable defibrillators. N Engl J Med 337 (1997) 1621-1623
175. Corrado D., Leoni L., Link M.S., et al. Implantable cardioverter-defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation 108 (2003) 3084-3091
176. DeSilva R.A. Central nervous system risk factors for sudden cardiac death. Ann N Y Acad Sci 382 (1982) 143-161
177. Cox G.F., and Kunkel L.M. Dystrophies and heart disease. Curr Opin Cardiol 12 (1997) 329-343
178. Pelargonio G., Dello R.A., Sanna T., et al. Myotonic dystrophy and the heart. Heart 88 (2002) 665-670
179. Munoz J., Sanjuan R., Morell J.S., et al. Ventricular tachycardia in Duchenne's muscular dystrophy. Int J Cardiol 54 (1996) 259-262
180. Samuels M.A. Neurally induced cardiac damage. Definition of the problem. Neurol Clin 11 (1993) 273-292
181. Merino J.L., and Peinado R. Arrhythmias associated with neuromuscular disorders. Card Electrophysiol Rev 6 (2002) 132-135
182. Becane H.M., Bonne G., Varnous S., et al. High incidence of sudden death with conduction system and myocardial disease due to lamins A and C gene mutation. Pacing Clin Electrophysiol 23 (2000) 1661-1666
183. Colleran J.A., Hawley R.J., Pinnow E.E., et al. Value of the electrocardiogram in determining cardiac events and mortality in myotonic dystrophy. Am J Cardiol 80 (1997) 1494-1497
184. Corrado G., Lissoni A., Beretta S., et al. Prognostic value of electrocardiograms, ventricular late potentials, ventricular arrhythmias, and left ventricular systolic dysfunction in patients with Duchenne muscular dystrophy. Am J Cardiol 89 (2002) 838-841
185. Ducceschi V., Nigro G., Sarubbi B., et al. Autonomic nervous system imbalance and left ventricular systolic dysfunction as potential candidates for arrhythmogenesis in Becker muscular dystrophy. Int J Cardiol 59 (1997) 275-279
186. Perloff J.K., Stevenson W.G., Roberts N.K., et al. Cardiac involvement in myotonic muscular dystrophy (Steinert's disease). a prospective study of 25 patients. Am J Cardiol 54 (1984) 1074-1081
187. Hiromasa S., Ikeda T., Kubota K., et al. Myotonic dystrophy. ambulatory electrocardiogram, electrophysiologic study, and echocardiographic evaluation. Am Heart J 113 (1987) 1482-1488
188. Stevenson W.G., Perloff J.K., Weiss J.N., et al. Facioscapulohumeral muscular dystrophy. evidence for selective, genetic electrophysiologic cardiac involvement. J Am Coll Cardiol 15 (1990) 292-299
189. James T.N., and Fisch C. Observations on the cardiovascular involvement in Friedreich's ataxia. Am Heart J 66 (1963) 164-175
190. Roberts N.K., Perloff J.K., and Kark R.A. Cardiac conduction in the Kearns-Sayre syndrome (a neuromuscular disorder associated with progressive external ophthalmoplegia and pigmentary retinopathy). Report of 2 cases and review of 17 published cases. Am J Cardiol 44 (1979) 1396-1400
191. Charles R., Holt S., Kay J.M., et al. Myocardial ultrastructure and the development of atrioventricular block in Kearns-Sayre syndrome. Circulation 63 (1981) 214-219
192. James T.N. Observations on the cardiovascular involvement, including the cardiac conduction system, in progressive muscular dystrophy. Am Heart J 63 (1962) 48-56
193. Bansch D., Antz M., Boczor S., et al. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy. the Cardiomyopathy Trial (CAT). Circulation 105 (2002) 1453-1458
194. Strickberger S.A., Hummel J.D., Bartlett T.G., et al. Amiodarone versus implantable cardioverter-defibrillator. randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia-AMIOVERT. J Am Coll Cardiol 41 (2003) 1707-1712
195. Cazeau S., Leclercq C., Lavergne T., et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 344 (2001) 873-880
196. Leon A.R., Abraham W.T., Curtis A.B., et al. Safety of transvenous cardiac resynchronization system implantation in patients with chronic heart failure. combined results of over 2,000 patients from a multicenter study program. J Am Coll Cardiol 46 (2005) 2348-2356
197. Online Mendelian Inheritance in Man, OMIM (TM). McKusick-Nathans Institute for Genectic Medicine, Johns Hopkins University (Baltimore, MD) and National Center for Biotechnology Information, National Library of Medicine (Bethesda, MD). Available at: http://www.ncbi.nlm.nih.gov/omim Accessed June 6, 2003.
198. Decision No. 1295/1999 EC of the European Parliament and of the Council of 29 April 1999. Official Journal of the European Communities; L155:1-5. Accessed June 22, 2003.
199. Moss A.J., Schwartz P.J., Crampton R.S., et al. The long QT syndrome. Prospective longitudinal study of 328 families. Circulation 84 (1991) 1136-1144
200. Kimbrough J., Moss A.J., Zareba W., et al. Clinical implications for affected parents and siblings of probands with long-QT syndrome. Circulation 104 (2001) 557-562
201. Priori S.G., Schwartz P.J., Napolitano C., et al. Risk stratification in the long-QT syndrome. N Engl J Med 348 (2003) 1866-1874
202. Splawski I., Timothy K.W., Sharpe L.M., et al. Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell 119 (2004) 19-31
203. Marks M.L., Whisler S.L., Clericuzio C., et al. A new form of long QT syndrome associated with syndactyly. J Am Coll Cardiol 25 (1995) 59-64
204. Moss A.J., Zareba W., Hall W.J., et al. Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome. Circulation 101 (2000) 616-623
205. Maron B.J., and Zipes D.P. Introduction. eligibility recommendations for competitive athletes with cardiovascular abnormalities-general considerations. J Am Coll Cardiol 45 (2005) 1318-1321
206. Napolitano C., Priori S.G., Schwartz P.J., et al. Genetic testing in the long QT syndrome. development and validation of an efficient approach to genotyping in clinical practice. JAMA 294 (2005) 2975-2980
207. Kannankeril P.J., Roden D.M., and Fish F.A. Suppression of bidirectional ventricular tachycardia and unmasking of prolonged QT interval with verapamil in Andersen's syndrome. J Cardiovasc Electrophysiol 15 (2004) 119
208. Brugada P., and Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. J Am Coll Cardiol 20 (1992) 1391-1396
209. Alings M., Dekker L., Sadee A., et al. Quinidine induced electrocardiographic normalization in two patients with Brugada syndrome. Pacing Clin Electrophysiol 24 (2001) 1420-1422
210. Mok N.S., Chan N.Y., and Chiu A.C. Successful use of quinidine in treatment of electrical storm in Brugada syndrome. Pacing Clin Electrophysiol 27 (2004) 821-823
211. Maury P., Couderc P., Delay M., et al. Electrical storm in Brugada syndrome successfully treated using isoprenaline. Europace 6 (2004) 130-133
212. Leenhardt A., Lucet V., Denjoy I., et al. Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year follow-up of 21 patients. Circulation 91 (1995) 1512-1519
213. Deal B.J., Miller S.M., Scagliotti D., et al. Ventricular tachycardia in a young population without overt heart disease. Circulation 73 (1986) 1111-1118
214. Proclemer A., Ciani R., and Feruglio G.A. Right ventricular tachycardia with left bundle branch block and inferior axis morphology. clinical and arrhythmological characteristics in 15 patients. Pacing Clin Electrophysiol 12 (1989) 977-989
215. Mehta D., Odawara H., Ward D.E., et al. Echocardiographic and histologic evaluation of the right ventricle in ventricular tachycardias of left bundle branch block morphology without overt cardiac abnormality. Am J Cardiol 63 (1989) 939-944
216. Morady F., Kadish A.H., DiCarlo L., et al. Long-term results of catheter ablation of idiopathic right ventricular tachycardia. Circulation 82 (1990) 2093-2099
217. O'Connor B.K., Case C.L., Sokoloski M.C., et al. Radiofrequency catheter ablation of right ventricular outflow tachycardia in children and adolescents. J Am Coll Cardiol 27 (1996) 869-874
218. Movsowitz C., Schwartzman D., Callans D.J., et al. Idiopathic right ventricular outflow tract tachycardia. narrowing the anatomic location for successful ablation. Am Heart J 131 (1996) 930-936
219. Lerman B.B., Belardinelli L., West G.A., et al. Adenosine-sensitive ventricular tachycardia. evidence suggesting cyclic AMP-mediated triggered activity. Circulation 74 (1986) 270-280
220. Lerman B.B. Response of nonreentrant catecholamine-mediated ventricular tachycardia to endogenous adenosine and acetylcholine. Evidence for myocardial receptor-mediated effects. Circulation 87 (1993) 382-390
221. Wilber D.J., Baerman J., Olshansky B., et al. Adenosine-sensitive ventricular tachycardia. Clinical characteristics and response to catheter ablation. Circulation 87 (1993) 126-134
222. Lemery R., Brugada P., Bella P.D., et al. Nonischemic ventricular tachycardia. Clinical course and long-term follow-up in patients without clinically overt heart disease. Circulation 79 (1989) 990-999
223. Goy J.J., Tauxe F., Fromer M., Schlapfer J., Vogt P., and Kappenberger L. Ten-year follow-up of 20 patients with idiopathic ventricular tachycardia. Pacing Clin Electrophysiol 13 (1990) 1142-1147
224. Krittayaphong R., Bhuripanyo K., Punlee K., et al. Effect of atenolol on symptomatic ventricular arrhythmia without structural heart disease. a randomized placebo-controlled study. Am Heart J 144 (2002) e10
225. Mont L., Seixas T., Brugada P., et al. Clinical and electrophysiologic characteristics of exercise-related idiopathic ventricular tachycardia. Am J Cardiol 68 (1991) 897-900
226. Hayashi H., Fujiki A., Tani M., et al. Circadian variation of idiopathic ventricular tachycardia originating from right ventricular outflow tract. Am J Cardiol 84 (1999) 99-101
227. Gill J.S., Blaszyk K., Ward D.E., et al. Verapamil for the suppression of idiopathic ventricular tachycardia of left bundle branch block-like morphology. Am Heart J 126 (1993) 1126-1133
228. Davidson S., and Surawicz B. Ectopic beats and atrioventricular conduction disturbances. In patients with hypopotassemia. Arch Intern Med 120 (1967) 280-285
229. Hollifield J.W. Thiazide treatment of hypertension. Effects of thiazide diuretics on serum potassium, magnesium, and ventricular ectopy. Am J Med 80 (1986) 8-12
230. Hollifield J.W. Thiazide treatment of systemic hypertension. effects on serum magnesium and ventricular ectopic activity. Am J Cardiol 63 (1989) 22G-25G
231. Podrid P.J. Potassium and ventricular arrhythmias. Am J Cardiol 65 (1990) 33E-44E
232. Dyckner T., Helmers C., and Wester P.O. Cardiac dysrhythmias in patients with acute myocardial infarction. Relation to serum potassium level and prior diuretic therapy. Acta Med Scand 216 (1984) 127-132
233. Nordrehaug J.E., and von der Lippe G. Hypokalaemia and ventricular fibrillation in acute myocardial infarction. Br Heart J 50 (1983) 525-529
234. Nordrehaug J.E., Johannessen K.A., and von der Lippe G. Serum potassium concentration as a risk factor of ventricular arrhythmias early in acute myocardial infarction. Circulation 71 (1985) 645-649
235. Kafka H., Langevin L., and Armstrong P.W. Serum magnesium and potassium in acute myocardial infarction. Influence on ventricular arrhythmias. Arch Intern Med 147 (1987) 465-469
236. Hulting J. In-hospital ventricular fibrillation and its relation to serum potassium. Acta Med Scand Suppl 647 (1981) 109-116
237. Thompson R.G., and Cobb L.A. Hypokalemia after resuscitation from out-of-hospital ventricular fibrillation. JAMA 248 (1982) 2860-2863
238. Glass J.D., McQuillen E.N., and Hardin N.J. Iatrogenic cardiac herniation. post mortem case. J Trauma 24 (1984) 632-633
239. Chadda K.D., Lichstein E., and Gupta P. Hypomagnesemia and refractory cardiac arrhythmia in a nondigitalized patient. Am J Cardiol 31 (1973) 98-100
240. Tzivoni D., Keren A., Cohen A.M., et al. Magnesium therapy for torsades de pointes. Am J Cardiol 53 (1984) 528-530
241. Solomon R.J. Ventricular arrhythmias in patients with myocardial infarction and ischaemia. Relationship to serum potassium and magnesium. Drugs 28 Suppl 1 (1984) 66-76
242. Sjogren A., Edvinsson L., and Fallgren B. Magnesium deficiency in coronary artery disease and cardiac arrhythmias. J Intern Med 226 (1989) 213-222
243. Rasmussen H.S., McNair P., Norregard P., et al. Intravenous magnesium in acute myocardial infarction. Lancet 1 (1986) 234-236
244. Abraham A.S., Rosenmann D., Kramer M., et al. Magnesium in the prevention of lethal arrhythmias in acute myocardial infarction. Arch Intern Med 147 (1987) 753-755
245. Rasmussen H.S., Suenson M., McNair P., et al. Magnesium infusion reduces the incidence of arrhythmias in acute myocardial infarction. A double-blind placebo-controlled study. Clin Cardiol 10 (1987) 351-356
246. Smith L.F., Heagerty A.M., Bing R.F., et al. Intravenous infusion of magnesium sulphate after acute myocardial infarction. effects on arrhythmias and mortality. Int J Cardiol 12 (1986) 175-183
247. Hollifield J.W. Magnesium depletion, diuretics, and arrhythmias. Am J Med 82 (1987) 30-37
248. Rajs J., Rajs E., and Lundman T. Unexpected death in patients suffering from eating disorders. A medico-legal study. Acta Psychiatr Scand 74 (1986) 587-596
249. Iseri L.T., Freed J., and Bures A.R. Magnesium deficiency and cardiac disorders. Am J Med 58 (1975) 837-846
250. Zwerling H.K. Does exogenous magnesium suppress myocardial irritability and tachyarrhythmias in the nondigitalized patient?. Am Heart J 113 (1987) 1046-1053
251. Spies C.D., Sander M., Stangl K., et al. Effects of alcohol on the heart. Curr Opin Crit Care 7 (2001) 337-343
252. Albert C.M., Manson J.E., Cook N.R., et al. Moderate alcohol consumption and the risk of sudden cardiac death among U.S. male physicians. Circulation 100 (1999) 944-950
253. Dyer A.R., Stamler J., Paul O., et al. Alcohol consumption, cardiovascular risk factors, and mortality in two Chicago epidemiologic studies. Circulation 56 (1977) 1067-1074
254. Wannamethee G., and Shaper A.G. Alcohol and sudden cardiac death. Br Heart J 68 (1992) 443-448
255. Ettinger P.O., Wu C.F., De La Cruz Jr. C., et al. Arrhythmias and the "Holiday Heart". alcohol-associated cardiac rhythm disorders. Am Heart J 95 (1978) 555-562
256. Chenet L., McKee M., Leon D., et al. Alcohol and cardiovascular mortality in Moscow. new evidence of a causal association. J Epidemiol Community Health 52 (1998) 772-774
257. Chenet L., Britton A., Kalediene R., et al. Daily variations in deaths in Lithuania. the possible contribution of binge drinking. Int J Epidemiol 30 (2001) 743-748
258. Shkolnikov V.M., McKee M., Chervyakov V.V., et al. Is the link between alcohol and cardiovascular death among young Russian men attributable to misclassification of acute alcohol intoxication? Evidence from the city of Izhevsk. J Epidemiol Community Health 56 (2002) 171-174
259. Wannamethee G., Shaper A.G., Macfarlane P.W., et al. Risk factors for sudden cardiac death in middle-aged British men. Circulation 91 (1995) 1749-1756
260. Sexton P.T., Walsh J., Jamrozik K., et al. Risk factors for sudden unexpected cardiac death in Tasmanian men. Aust N Z J Med 27 (1997) 45-50
261. Jouven X., Desnos M., Guerot C., et al. Predicting sudden death in the population. the Paris Prospective Study I. Circulation 99 (1999) 1978-1983
262. Escobedo L.G., and Caspersen C.J. Risk factors for sudden coronary death in the United States. Epidemiology 8 (1997) 175-180
263. Kannel W.B., and Schatzkin A. Sudden death. lessons from subsets in population studies. J Am Coll Cardiol 5 (1985) 141B-149B
264. Shepherd J., Cobbe S.M., Ford I., et al., West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333 (1995) 1301-1307
265. Downs J.R., Clearfield M., Weis S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279 (1998) 1615-1622
266. Jouven X., Charles M.A., Desnos M., et al. Circulating nonesterified fatty acid level as a predictive risk factor for sudden death in the population. Circulation 104 (2001) 756-761
267. Fuller C.M., McNulty C.M., Spring D.A., et al. Prospective screening of 5,615 high school athletes for risk of sudden cardiac death. Med Sci Sports Exerc 29 (1997) 1131-1138
268. Fuller C.M. Cost effectiveness analysis of screening of high school athletes for risk of sudden cardiac death. Med Sci Sports Exerc 32 (2000) 887-890
269. Ebert S.N., Liu X.K., and Woosley R.L. Female gender as a risk factor for drug-induced cardiac arrhythmias. evaluation of clinical and experimental evidence. J Womens Health 7 (1998) 547-557
270. Widerhorn J., Widerhorn A.L., Rahimtoola S.H., et al. WPW syndrome during pregnancy. increased incidence of supraventricular arrhythmias. Am Heart J 123 (1992) 796-798
271. Tawam M., Levine J., Mendelson M., et al. Effect of pregnancy on paroxysmal supraventricular tachycardia. Am J Cardiol 72 (1993) 838-840
272. Lee S.H., Chen S.A., Wu T.J., et al. Effects of pregnancy on first onset and symptoms of paroxysmal supraventricular tachycardia. Am J Cardiol 76 (1995) 675-678
273. Brodsky M., Doria R., Allen B., et al. New-onset ventricular tachycardia during pregnancy. Am Heart J 123 (1992) 933-941
274. Gowda R.M., Khan I.A., Mehta N.J., et al. Cardiac arrhythmias in pregnancy. clinical and therapeutic considerations. Int J Cardiol 88 (2003) 129-133
275. Aronow W.S. Treatment of ventricular arrhythmias in older adults. J Am Geriatr Soc 43 (1995) 688-695
276. Cairns J.A., Connolly S.J., Roberts R., et al., Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations. CAMIAT. Lancet 349 (1997) 675-682
277. Fleg J.L., and Kennedy H.L. Cardiac arrhythmias in a healthy elderly population. detection by 24-hour ambulatory electrocardiography. Chest 81 (1982) 302-307
278. Lee K.L., and Tai Y.T. Long-term low-dose amiodarone therapy in the management of ventricular and supraventricular tachyarrhythmias. efficacy and safety. Clin Cardiol 20 (1997) 372-377
279. Aronow W.S., Ahn C., Mercando A.D., et al. Prevalence and association of ventricular tachycardia and complex ventricular arrhythmias with new coronary events in older men and women with and without cardiovascular disease. J Gerontol A Biol Sci Med Sci 57 (2002) M178-M180
280. Volpi A., Cavalli A., Turato R., et al. Incidence and short-term prognosis of late sustained ventricular tachycardia after myocardial infarction. results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI-3) Data Base. Am Heart J 142 (2001) 87-92
281. Kannel W.B., Cupples L.A., and D'Agostino R.B. Sudden death risk in overt coronary heart disease. the Framingham Study. Am Heart J 113 (1987) 799-804
282. Kuller L., Lilienfeld A., and Fisher R. Epidemiological study of sudden and unexpected deaths due to arteriosclerotic heart disease. Circulation 34 (1966) 1056-1068
283. Geelen P., Lorga F.A., Primo J., et al. Experience with implantable cardioverter defibrillator therapy in elderly patients. Eur Heart J 18 (1997) 1339-1342
284. Panotopoulos P.T., Axtell K., Anderson A.J., et al. Efficacy of the implantable cardioverter-defibrillator in the elderly. J Am Coll Cardiol 29 (1997) 556-560
285. Saksena S., Mathew P., Giorgberidze I., et al. Implantable defibrillator therapy for the elderly. Am J Geriatr Cardiol 7 (1998) 11-13
286. Silka M.J., Kron J., Dunnigan A., et al., The Pediatric Electrophysiology Society. Sudden cardiac death and the use of implantable cardioverter-defibrillators in pediatric patients. Circulation 87 (1993) 800-807
287. Sellers Jr. T.D., Bashore T.M., and Gallagher J.J. Digitalis in the pre-excitation syndrome. Analysis during atrial fibrillation. Circulation 56 (1977) 260-267
288. Garson Jr. A., Gillette P.C., Titus J.L., et al. Surgical treatment of ventricular tachycardia in infants. N Engl J Med 310 (1984) 1443-1445
289. Davis A.M., Gow R.M., McCrindle B.W., et al. Clinical spectrum, therapeutic management, and follow-up of ventricular tachycardia in infants and young children. Am Heart J 131 (1996) 186-191
290. Pfammatter J.P., and Paul T. Idiopathic ventricular tachycardia in infancy and childhood: a multicenter study on clinical profile and outcome. Working Group on Dysrhythmias and Electrophysiology of the Association for European Pediatric Cardiology. J Am Coll Cardiol 33 (1999) 2067-2072
291. Roden D.M., and Anderson M.E. Proarrhythmia. In: Kass R.S., and Clancey C.E. (Eds). Handbook of Experimental Pharmacology: vol. 171. Basis and Treatment of Cardiac Arrhythmias (2006), Springer Verlag, Boston, MA 288-304
292. Antman E.M., Wenger T.L., Butler Jr. V.P., et al. Treatment of 150 cases of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments. Final report of a multicenter study. Circulation 81 (1990) 1744-1752
293. Splawski I., Timothy K.W., Tateyama M., et al. Variant of SCN5A sodium channel implicated in risk of cardiac arrhythmia. Science 297 (2002) 1333-1336
294. Yang P., Kanki H., Drolet B., et al. Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation 105 (2002) 1943-1948
295. Tzivoni D., Banai S., Schuger C., et al. Treatment of torsade de pointes with magnesium sulfate. Circulation 77 (1988) 392-397
296. Roden D.M. Drug-induced prolongation of the QT interval. N Engl J Med 350 (2004) 1013-1022
297. Bajaj A.K., Woosley R.L., and Roden D.M. Acute electrophysiologic effects of sodium administration in dogs treated with O-desmethyl encainide. Circulation 80 (1989) 994-1002
298. Chouty F., Funck-Brentano C., Landau J.M., et al. [Efficacy of high doses of molar lactate by the venous route in flecainide poisoning]. Presse Med 16 (1987) 808-810
299. Myerburg R.J., Kessler K.M., Cox M.M., et al. Reversal of proarrhythmic effects of flecainide acetate and encainide hydrochloride by propranolol. Circulation 80 (1989) 1571-1579
300. Tada H., Sticherling C., Oral H., et al. Brugada syndrome mimicked by tricyclic antidepressant overdose. J Cardiovasc Electrophysiol 12 (2001) 275
301. Hoffman J.R., Votey S.R., Bayer M., et al. Effect of hypertonic sodium bicarbonate in the treatment of moderate-to-severe cyclic antidepressant overdose. Am J Emerg Med 11 (1993) 336-341
302. Lipshultz S.E., Lipsitz S.R., Mone S.M., et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 332 (1995) 1738-1743
303. Steinherz L.J., Steinherz P.G., and Tan C. Cardiac failure and dysrhythmias 6 to 19 years after anthracycline therapy. a series of 15 patients. Med Pediatr Oncol 24 (1995) 352-361
304. Ferrari E., Benhamou M., and Baudouy M. [Cardiotoxicity associated with trastuzumab (herceptin). An undesired effect leads towards a model of cardiac insufficiency]. Arch Mal Coeur Vaiss 97 (2004) 333-337
305. Suter T.M., Cook-Bruns N., and Barton C. Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer. Breast 13 (2004) 173-183
306. Pichon M.F., Cvitkovic F., Hacene K., et al. Drug-induced cardiotoxicity studied by longitudinal B-type natriuretic peptide assays and radionuclide ventriculography. In Vivo 19 (2005) 567-576
307. Bu'Lock F.A., Mott M.G., Oakhill A., et al. Early identification of anthracycline cardiomyopathy. possibilities and implications. Arch Dis Child 75 (1996) 416-422
308. Li C.K., Sung R.Y., Kwok K.L., et al. A longitudinal study of cardiac function in children with cancer over 40 months. Pediatr Hematol Oncol 17 (2000) 77-83
309. De W.D., Suys B., Maurus R., et al. Dobutamine stress echocardiography in the evaluation of late anthracycline cardiotoxicity in childhood cancer survivors. Pediatr Res 39 (1996) 504-512
310. Klewer S.E., Goldberg S.J., Donnerstein R.L., et al. Dobutamine stress echocardiography. a sensitive indicator of diminished myocardial function in asymptomatic doxorubicin-treated long-term survivors of childhood cancer. J Am Coll Cardiol 19 (1992) 394-401
311. Lenk M.K., Zeybek C., Okutan V., et al. Detection of early anthracycline-induced cardiotoxicity in childhood cancer with dobutamine stress echocardiography. Turk J Pediatr 40 (1998) 373-383
312. Johnson G.L., Moffett C.B., Geil J.D., et al. Late echocardiographic findings following childhood chemotherapy with normal serial cardiac monitoring. J Pediatr Hematol Oncol 18 (1996) 72-75
313. Postma A., Elzenga N.J., Haaksma J., et al. Cardiac status in bone tumor survivors up to nearly 19 years after treatment with doxorubicin. a longitudinal study 1. Med Pediatr Oncol 39 (2002) 86-92
314. Robben N.C., Pippas A.W., and Moore J.O. The syndrome of 5-fluorouracil cardiotoxicity. An elusive cardiopathy. Cancer 71 (1993) 493-509